Real-Life Management of Elevated Troponin Level in Patients Treated with Immune Checkpoint Inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical outcomes of cancer. Nevertheless, their use may lead to myocardial injury. The 2022 European Society of Cardiology cardio-oncology guidelines recommend routine follow-up of troponin level; however, current guidelines do not provide specific protocols for managing elevated troponin levels during ICI therapy. We aimed to describe the real-life assessment of patients treated with ICIs, presenting with an elevated high-sensitivity troponin I (hs-TnI) level following therapy.

Methods

Tel Aviv Sourasky Medical Center has implemented a routine follow-up of hs-TnI level measurement during ICI therapy. We performed a retrospective analysis evaluating the clinical assessment and management of patients pres

SUBMITTER: Zornitzki L 

PROVIDER: S-EPMC12399054 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature